BriaCell Therapeutics (NASDAQ:BCTX) Given New $32.00 Price Target at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX) had its target price upped by HC Wainwright from $15.00 to $32.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

BriaCell Therapeutics Stock Up 0.4 %

NASDAQ BCTX opened at $5.04 on Monday. BriaCell Therapeutics has a 12-month low of $4.66 and a 12-month high of $65.25. The stock has a market capitalization of $14.87 million, a PE ratio of -0.38 and a beta of 1.59. The company has a 50 day moving average price of $9.09 and a two-hundred day moving average price of $10.42.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10). As a group, equities analysts anticipate that BriaCell Therapeutics will post -15.14 EPS for the current year.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. increased its stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,000 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Vontobel Holding Ltd. owned about 0.25% of BriaCell Therapeutics worth $62,000 at the end of the most recent reporting period. 15.42% of the stock is owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.